GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-20-8047-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$41.14 billion
Profitability
Miscellaneous
Employees95,490
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions
What is GlaxoSmithKline's stock symbol?
GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."
How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?
GlaxoSmithKline announced a quarterly dividend on Friday, May 3rd. Stockholders of record on Friday, May 17th will be paid a dividend of $0.4953 per share on Thursday, July 11th. This represents a $1.98 annualized dividend and a dividend yield of 4.69%. The ex-dividend date of this dividend is Thursday, May 16th. View GlaxoSmithKline's Dividend History.
How were GlaxoSmithKline's earnings last quarter?
GlaxoSmithKline plc (NYSE:GSK) announced its earnings results on Wednesday, July, 24th. The pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.64 by $0.14. The pharmaceutical company earned $10.04 billion during the quarter, compared to analyst estimates of $9.55 billion. GlaxoSmithKline had a return on equity of 175.45% and a net margin of 13.84%. View GlaxoSmithKline's Earnings History.
When is GlaxoSmithKline's next earnings date?
What guidance has GlaxoSmithKline issued on next quarter's earnings?
GlaxoSmithKline issued an update on its FY 2019 earnings guidance on Wednesday, July, 24th. The company provided EPS guidance of $1.42-1.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.88.
What price target have analysts set for GSK?
15 Wall Street analysts have issued 12 month price targets for GlaxoSmithKline's stock. Their forecasts range from $36.95 to $45.00. On average, they expect GlaxoSmithKline's stock price to reach $41.24 in the next twelve months. This suggests that the stock has a possible downside of 2.5%. View Analyst Price Targets for GlaxoSmithKline.
What is the consensus analysts' recommendation for GlaxoSmithKline?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 1 sell rating, 11 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.
Has GlaxoSmithKline been receiving favorable news coverage?
News headlines about GSK stock have been trending very negative on Thursday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. GlaxoSmithKline earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave headlines about the pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for GlaxoSmithKline.
Who are some of GlaxoSmithKline's key competitors?
Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).
What other stocks do shareholders of GlaxoSmithKline own?
Who are GlaxoSmithKline's key executives?
GlaxoSmithKline's management team includes the folowing people:
- Ms. Emma N. Walmsley, CEO & Director (Age 49)
- Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)
- Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)
- Mr. Jack Bailey, Pres of US Pharmaceuticals
- Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)
Who are GlaxoSmithKline's major shareholders?
GlaxoSmithKline's stock is owned by a number of of retail and institutional investors. Top institutional investors include Welch & Forbes LLC (0.03%), Douglas Lane & Associates LLC (0.02%), Confluence Investment Management LLC (0.01%), Keystone Financial Planning Inc. (0.01%), Ferguson Wellman Capital Management Inc. (0.01%) and Hennessy Advisors Inc. (0.00%). View Institutional Ownership Trends for GlaxoSmithKline.
Which institutional investors are selling GlaxoSmithKline stock?
GSK stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Global Trust Asset Management LLC, Confluence Investment Management LLC, CIBC Private Wealth Group LLC, Old North State Trust LLC, Hennessy Advisors Inc., Stock Yards Bank & Trust Co. and Stonebridge Capital Management Inc.. View Insider Buying and Selling for GlaxoSmithKline.
Which institutional investors are buying GlaxoSmithKline stock?
GSK stock was bought by a variety of institutional investors in the last quarter, including Douglas Lane & Associates LLC, Fox Run Management L.L.C., Pacer Advisors Inc., Nachman Norwood & Parrott Inc, Ferguson Wellman Capital Management Inc., Advisor Partners LLC, Keystone Financial Planning Inc. and Juncture Wealth Strategies LLC. View Insider Buying and Selling for GlaxoSmithKline.
How do I buy shares of GlaxoSmithKline?
Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is GlaxoSmithKline's stock price today?
One share of GSK stock can currently be purchased for approximately $42.28.
How big of a company is GlaxoSmithKline?
GlaxoSmithKline has a market capitalization of $105.46 billion and generates $41.14 billion in revenue each year. The pharmaceutical company earns $4.84 billion in net income (profit) each year or $3.16 on an earnings per share basis. GlaxoSmithKline employs 95,490 workers across the globe.View Additional Information About GlaxoSmithKline.
What is GlaxoSmithKline's official website?
How can I contact GlaxoSmithKline?
GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]
MarketBeat Community Rating for GlaxoSmithKline (NYSE GSK)
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.
